Alnylam Pharmaceuticals Inc
ALNY251.560USD
+8.949+3.69%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
32.53BMarket Cap
LossP/E TTM
More Details of Alnylam Pharmaceuticals Inc Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Company Info
Company codeALNY
Company nameAlnylam Pharmaceuticals Inc
IPO dateMay 28, 2004
Founded at2003
CEODr. Yvonne L. Greenstreet, M.D.
Number of employees2230
Security typeOrdinary Share
Fiscal year-endMay 28
Address675 W Kendall St
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142-1168
Phone16175518200
Websitehttps://www.alnylam.com/
Company codeALNY
IPO dateMay 28, 2004
Founded at2003
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
By RegionUSD
Name
Revenue
Proportion
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Shareholder Statistics
Shareholder
Proportion
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Type
Shareholder
Proportion
Investment Advisor
56.07%
Investment Advisor/Hedge Fund
32.20%
Corporation
3.44%
Hedge Fund
2.58%
Sovereign Wealth Fund
1.97%
Pension Fund
1.43%
Bank and Trust
1.19%
Research Firm
1.07%
Individual Investor
0.43%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1235
131.13M
100.81%
-458.58K
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Wellington Management Company, LLP
4.20M
3.23%
-756.72K
-15.28%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
Dodge & Cox
3.54M
2.72%
-82.27K
-2.27%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Tema Neuroscience and Mental Health ETF
4.39%
VanEck Biotech ETF
4.19%
Global X Genomics & Biotechnology ETF
3.91%
ProShares Ultra Nasdaq Biotechnology
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.23%
iShares Biotechnology ETF
3.11%
Invesco Nasdaq Biotechnology ETF
3.05%
Franklin Genomic Advancements ETF
2.56%
American Century Focused Dynamic Growth ETF
2.52%
SPDR S&P Biotech ETF
2.5%
View more
Tema Neuroscience and Mental Health ETF
Proportion4.39%
VanEck Biotech ETF
Proportion4.19%
Global X Genomics & Biotechnology ETF
Proportion3.91%
ProShares Ultra Nasdaq Biotechnology
Proportion3.49%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.23%
iShares Biotechnology ETF
Proportion3.11%
Invesco Nasdaq Biotechnology ETF
Proportion3.05%
Franklin Genomic Advancements ETF
Proportion2.56%
American Century Focused Dynamic Growth ETF
Proportion2.52%
SPDR S&P Biotech ETF
Proportion2.5%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data